Positions

Overview

  • Dr. Amm received her BS in Biological Sciences from Saint Mary’s College and Ph.D. in Pharmacology and Toxicology from UAB with a focus on cancer biology and novel therapeutics. Dr. Amm completed the Dental Academic Research Training (DART) program as a post-doctoral scholar in the laboratory of Dr. Mary MacDougall and was a Mentored Experiences in Research, Instruction, and Teaching (MERIT) program Scholar-at-Large, which provided teaching experiences at a minority-partner institution. During her postdoctoral studies, she has collaborated on projects related to the genetic and molecular basis of craniofacial diseases, particularly odontogenic tumors. She has characterized numerous cellular models of odontogenic tumors and developed new in vivo models. In March 2017, she joined the faculty the Oral and Maxillofacial Surgery Department at UAB. Her work has been funded by the Department of Defense, Oral and Maxillofacial Surgery Foundation, and NIDCR. Her current research focuses on genetics and signaling pathways that play a role in the pathogenesis of human oral cancers and odontogenic tumors with a goal to develop targeted therapies and diagnostic tools.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 89Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model.  Scientific Reports.  12. 2022
    2020 The use of hedgehog antagonists in cancer therapy: a comparison of clinical outcomes and gene expression analyses.  Cancer Biology and Therapy.  21:873-883. 2020
    2020 Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study.  Journal of oral surgery, anesthesia, and hospital dental service.  78:1736-1747. 2020
    2020 Mandibular undifferentiated pleomorphic sarcoma: Molecular analysis of a primary cell population.  Clinical and Experimental Dental Research.  6:495-505. 2020
    2020 Comparison of panitumumab-IRDye800CW and 5-aminolevulinic acid to provide optical contrast in a model of glioblastoma multiforme.  Molecular Cancer Therapeutics.  19:1922-1929. 2020
    2016 Molecular Signaling in Benign Odontogenic Neoplasia Pathogenesis.  Current Oral Health Reports.  3:82-92. 2016
    2014 Establishment and characterization of a primary calcifying epithelial odontogenic tumor cell population.  Journal Of Oral Pathology and Medicine.  43:183-190. 2014
    2014 Establishment of Singleton-Merten Syndrome pulp cells: Evidence of mineralization dysregulation.  Connective Tissue Research.  55:57-61. 2014
    2014 Matrix metalloproteinase expression in keratocystic odontogenic tumors and primary cells.  Connective Tissue Research.  55:97-101. 2014
    2014 Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.  Oncotarget.  5:7065-7080. 2014
    2013 Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.  Annals of Surgical Oncology.  20:3059-3065. 2013
    2012 Targeting the sonic hedgehog pathway in keratocystic odontogenic tumor.  Journal of Biological Chemistry.  287:27117-27125. 2012
    2012 MiR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors.  Cellular Oncology.  35:285-291. 2012
    2011 Differential enamel and osteogenic gene expression profiles in odontogenic tumors 2011
    2011 Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer 2011
    2011 Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.  Gynecologic Oncology.  121:193-199. 2011
    2011 Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells.  Molecular Cancer Research.  9:403-417. 2011
    2011 Combined modality therapy with TRAIL or agonistic death receptor antibodies.  Cancer Biology and Therapy.  11:431-449. 2011
    2010 Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer.  Cancer Biology and Therapy.  10:893-902. 2010

    Education And Training

  • UAB Institute of Oral Health Research, Postdoctoral Fellowship
  • Doctor of Philosophy in Pharmacology and Toxicology, University of Alabama at Birmingham 2010
  • Bachelor of Science or Mathematics in Biology / Biological Sciences, Saint Mary's College 2002

    • Full Name

  • Hope Amm